The global vaccine adjuvants market is anticipated to reach USD 0.96 billion in 2029 from USD 0.70 billion in 2024, with a significant CAGR of 6.5%. The major factors contributing towards the growth of the vaccine adjuvants market include a surge in therapeutic cancer vaccines, growth in Pediatric Vaccination Programs, advancements in adjuvant technologies such as TLR agonists and increased demand for combination and multivalent vaccines.
The product segment is further segmented into emulsion-based adjuvants, pathogen components, saponin-based adjuvants, particulate-based adjuvants, and others. The emulsion-based adjuvants dominated the market in 2023 owing to versatility in antigen platforms, scalability, and manufacturing feasibility, and the rise in regulatory approvals for emulsion-based adjuvant vaccines. Saponin-based adjuvants is gaining prominence due to unique immunostimulatory properties and compatibility with modern vaccine platforms.
The global vaccine adjuvant market is segmented into organic and inorganic vaccine adjuvants based on adjuvant type. Organic vaccine adjuvants dominated the market in 2023 owing to their enhanced safety profiles, biocompatibility, and ability to stimulate robust immune responses without adverse effects. Furthermore, growing regulatory support for natural, non-toxic components further accelerates the adoption of organic adjuvants across various vaccine types.
Based on application, the global vaccine adjuvants market is segmented into commercial and research. The research segment dominated the market due to the increased use of adjuvants in preclinical and clinical studies to evaluate vaccine efficacy and immune responses. Furthermore, the rise of academic-industry collaborations and increased research on therapeutic vaccines is projecting growth of the segment. However, increasing demand for vaccines across various industries, including human and veterinary care, and a rise in the incorporation of adjuvants to improve vaccine performance by key players are likely to impact the growth of the commercial application segment.
The market is segmented by region into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America dominated the vaccine adjuvants market in 2023, and the Asia Pacific region is likely to grow at a significant CAGR during the forecast period. North America’s dominance in the adjuvant market is attributed to strong pharmaceutical industry, advanced healthcare infrastructure, and substantial investment in vaccine research and development. APAC region is experiencing significant growth, fueled by increasing healthcare investments, prioritization of vaccination programs, and the growing presence of vaccine manufacturers in emerging markets in the APAC region.
Major players operating in the vaccine adjuvants market include GSK Plc (UK), SEPPIC (France), Croda International Plc (UK), SPI Pharma (UK), Agenus Inc. (US), Phibro Animal Health Corporation (US), Aurorium (US), Dynavax Technologies Corporation (US), Novavax (US), Merck KGaA (Germany) and among others.
